What is Thalassemia Intermedia Care in India?

Thalassemia Intermedia Care in India: Cost, Treatment & Support

Thalassemia is a genetic blood condition in which the body cannot produce enough healthy haemoglobin, the part of red blood cells that carries oxygen. As a result, people with thalassemia often have fewer red blood cells and lower haemoglobin levels than normal, which can lead to anaemia and other health issues. 

Individuals with thalassemia intermedia may not require regular blood transfusions but can still develop complications such as anaemia and iron overload, often due to increased iron absorption rather than transfusions alone. Several healthcare facilities offer excellent care and treatment options for this condition in India. 

Keep reading to learn more about the care and treatment options for thalassemia intermedia in India. 

What are the Core Care Components of Thalassemia Intermedia in India? 

India is well known for its healthcare infrastructure and numerous specialised hospitals that provide thorough treatment for thalassaemia. The cost of managing thalassemia intermedia in India varies widely depending on the severity and treatment type. Routine care (including iron chelation, occasional transfusions, and monitoring) may cost between ₹1.5 lakhs to ₹4 lakhs annually. Bone marrow transplant, if considered, may cost ₹10–30 lakhs depending on the hospital and donor type. 

These expenses may differ based on the nature of the treatment and the hospital’s location. However, thalassaemia care in India remains significantly more cost-effective compared to most Western nations. 

Given below are the various treatment approaches for thalassemia intermedia: 

1. Iron Chelation Therapy 

Since repeated transfusions can cause iron build-up, patients usually need iron chelation therapy to remove the extra iron. Medicines such as Deferasirox or Deferoxamine are commonly used and help keep iron levels in check, protecting vital organs like the heart and liver. 

2. Regular Blood Transfusions 

While patients with beta thalassemia major require regular transfusions, patients with thalassemia intermedia usually require transfusions only intermittently, depending on symptoms and complications. When transfusions are required, they are usually given intermittently and not on a weekly basis in thalassemia intermedia. While transfusions help manage anaemia, they can also lead to an excess of iron in the body over time, which may damage organs if not controlled properly. 

3. Folic Acid Supplements 

Folic acid is often recommended to support the production of red blood cells. It’s beneficial for patients who receive transfusions regularly, as it contributes to overall blood health and helps manage fatigue and weakness. 

4. Bone Marrow or Stem Cell Transplant 

A bone marrow or stem cell transplant offers a possible cure, especially for younger patients with a matching donor. The procedure involves replacing the patient’s damaged bone marrow with healthy stem cells from a compatible donor, allowing the body to produce normal blood cells. 

5. Gene Therapy 

Gene therapy is an emerging treatment under clinical evaluation and is not yet widely available or routinely accessible in India. By introducing functional genes into the patient’s cells, this method can potentially restore proper haemoglobin production and significantly reduce the need for transfusions. 

If left untreated, thalassaemia can lead to serious health issues such as heart complications, liver damage, and a higher risk of infections. That’s why early diagnosis and proper treatment are crucial for managing the disease. 

Care and treatment for thalassemia intermedia in India is both hopeful and accessible. Early diagnosis via a thalassemia profile enables timely management with minimal delay.  

Reader Information: The information provided in this article is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Thalassemia intermedia is a complex medical condition, and its management may vary based on individual health status, severity of the disease, age, and other clinical factors. Readers are advised to consult a qualified haematologist or healthcare professional for personalised medical guidance and before making any decisions related to diagnosis, treatment, or healthcare planning.